Ranbaxy has launched an anti-malarial drug billed by CEO Arun Sawhney as “India’s first new chemical entity developed through clinical trials and commercialization in India”. Synriam, priced at Rs. 130 for three tablets, is a three-day course. The three-tablet module sets it apart from alternative therapies which require a 2-4 tablet dosage per day. Addressing the issue of price compared to competitors in the same category, Sawhney said that the drug is “the most economic therapy for malaria from the available options...there are some drugs that are priced at Rs.250 so compared to that this will be half of that.”
